Clinical trials: Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Trial of CF101 to Treat Patients With Dry Eye Disease
Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.
- Trial name
- NCT01235234
- Testing
- CF101
- Where
- Israel
- Volunteers
- 236 people
- Sponsor
- Can-Fite BioPharma
Dry Eye, Dry Eye Syndrome of Unspecified Lacrimal Gland
Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects.
Title of the study: Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic gel PRO-167 versus Corneregel®, on the ocular surface of ophthalmological and clinically healthy subjects.
- Trial name
- PRO-167/I (NCT03520348)
- Testing
- PRO-167, Corneregel
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye
Keratometric Tear Breakup Time and Fluorescein Tear Breakup Time
The purpose of the research is to determine if putting fluorescein onto the eye (most common test done for dry eye syndrome) is an accurate way to measure dry eye symptoms.
- Trial name
- NCT00854906
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Dry Eye Disease
Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or…
- Trial name
- NCT02824913
- Testing
- P-321 Ophthalmic Solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Parion Sciences
Dry Eye
Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery
This study is designed to assess the tolerability and comfort of peri-operative 0.3% hypromellose eye drops in LASIK surgery patients and to assess whether pre-operative 0.3% hypromellose eye drops add to post-operative comfort…
- Trial name
- NCT00909324
- Testing
- Pre-LASIK 0.3% hypromellose, Post-LASIK 0.3% hypromellose
- Where
- India
- Volunteers
- 170 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eyes
Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics
The purpose is to compare the prevalence of dry eyes in diabetics and non diabetics. This might help identify a group of patients at greater risk for dry eye complications.
- Trial name
- NCT01450787
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- COA Research Foundation, INC
Dry Eye
Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease
The purpose of this clinical trial is to investigate the efficacy of a single iLux® treatment in symptomatic CL wearers who have DED (according to the TFOS DEWS II diagnostic criteria), of the evaporative dry eye disease subtype…
- Trial name
- SHEEPDOG (NCT04159935)
- Testing
- iLux® system
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Waterloo
Evaporative Dry Eye
iLux Treatment for Meibomian Gland Dysfunction (MGD)
The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.
- Trial name
- NCT03055650
- Testing
- iLux 2020 System
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tear Film Innovations, Inc.
Sjogren's Syndrome
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
- Trial name
- NCT00631358
- Testing
- Maxidex, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Dry Eye Syndrome
Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.
The objective is to demonstrate the non-inferiority of T2769 compared to Hylo-Forte® in terms of the change from baseline (D1) in total ocular surface staining score assessed on Oxford 0-15 scale, in the study eye at the D36…
- Trial name
- NCT06375499
- Testing
- T2769, Hylo-Forte®
- Where
- 4 sites in Czechia, Hungary
- Volunteers
- 74 people
- Sponsor
- Laboratoires Thea
Dry Eye
Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.
Phase IV, non inferiority, controlled, open, multicenter clinical study to compare the efficacy of the Ophthalmic Solution Humylub Ofteno® PF against Hyabak® and Lagricel Ofteno® PF applied quater in die (QID) for 30 days in…
- Trial name
- PRO-087 (NCT04702776)
- Testing
- Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%, Sodium hyaluronate 0.15%, Sodium hyaluronate 0.4%
- Where
- Mexico
- Volunteers
- 182 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye
Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers
to evaluate tears between habitual contact lens wearers and non contact lens wearers
- Trial name
- NCT01317030
- Testing
- Contact Lens Wear, Non-Contact Lens Wear
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Keratoconjunctivitis Sicca, Dry Eye Disease
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry…
- Trial name
- NCT02254265
- Testing
- OTX-101 0.05%, OTX-101 0.09%, Vehicle
- Where
- United States
- Volunteers
- 455 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Disease (DED)
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).
- Trial name
- NCT04393441
- Testing
- 011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
- Where
- 26 sites in United States
- Volunteers
- 400 people
- Sponsor
- Allergan
Dry Eye
RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears
The RPS InflammaDry Detector™ is intended to detect elevated MMP-9 in human tears to aid in the diagnosis of patients with signs or symptoms of dry eye disease, in conjunction with other methods of clinical evaluation.
- Trial name
- NCT01313351
- Testing
- RPS InflammaDry Detector™
- Where
- 8 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Rapid Pathogen Screening
Sjögren Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
This was an adaptive design phase 2 study to establish safety and efficacy; and to characterize the dose-response of LOU064 in subjects with moderate to severe Sjögren's syndrome.
- Trial name
- LOUiSSe (NCT04035668)
- Testing
- Remibrutinib
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndrome
Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects
This study will evaluate the safety, efficacy, and acceptability of two artificial tears compared to a currently available artificial tear in subjects with dry eye.
- Trial name
- NCT01010282
- Testing
- Glycerin and Polysorbate 80 based artificial tear, Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Allergan
Dry Eye Syndromes
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
Objective: To assess the safety and tolerability of the PRO-165 formulation on the ocular surface of ophthalmologically and clinically healthy subjects.
- Trial name
- PRO-165 (NCT03697876)
- Testing
- PRO-165, Artelac
- Where
- Mexico
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Keratoconjunctivitis Sicca
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
This study will evaluate the efficacy of cyclosporine ophthalmic solution vs. other non-prescription treatments in patients with dry eye disease.
- Trial name
- NCT00717418
- Testing
- cyclosporine ophthalmic emulsion 0.05%, artificial tears
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Allergan
Dry Eye Syndrome
Study of SkQ1 as Treatment for Dry-eye Syndrome
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- VISTA-1 (NCT03764735)
- Testing
- Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
- Where
- 7 sites in United States
- Volunteers
- 452 people
- Sponsor
- Mitotech, SA